Amicus Therapeutics, Inc. (FOLD)
Price:
8.26 USD
( + 0.10 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
NEWS
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy
zacks.com
2025-10-07 13:01:13Amicus Therapeutics (FOLD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns
zacks.com
2025-10-06 10:26:18Broker upgrades fuel optimism for Amicus Therapeutics, Micron and General Dynamics as earnings outlook strengthens.
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
zacks.com
2025-10-02 10:41:58Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.
3 Of My Favorite Biotech Stocks Under $10
seekingalpha.com
2025-09-29 13:15:09Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
zacks.com
2025-09-25 12:31:13Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?
zacks.com
2025-09-19 10:36:09Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
seekingalpha.com
2025-09-09 18:06:20Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 3:20 PM EDT Company Participants Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Okay. Great. I'm Max Skor, a biotech analyst with Morgan Stanley.
In NCLA Amicus Win, en Banc Federal Circuit Rules Trump's Emergency Tariffs Are Unlawful
globenewswire.com
2025-08-29 21:06:00V.O.S. Selections, Inc.; Plastic Services and Products, LCC, d/b/a Genova Pipe; MicroKits, LCC; FishUSA Inc.; Terry Precision Cycling LLC v. President Donald J. Trump, et al. V.O.S. Selections, Inc.; Plastic Services and Products, LCC, d/b/a Genova Pipe; MicroKits, LCC; FishUSA Inc.; Terry Precision Cycling LLC v. President Donald J. Trump, et al.
Multiple Jewish Organizations File Second Circuit Amicus Brief in Support of Previously Detained Tufts Student
businesswire.com
2025-08-25 16:22:00SEATTLE--(BUSINESS WIRE)--A coalition of American Jewish organizations have filed an amicus brief in the United States Court of Appeals for the Second Circuit in support of a Vermont federal court's consideration of Rümeysa Öztürk's habeas petition objecting to her then-detention. Öztürk, a Turkish national and PhD student at Tufts University, was detained this spring and held in an ICE facility in Louisiana for six weeks before a federal judge ordered her release. Öztürk was arrested under a r.
In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump
globenewswire.com
2025-08-21 18:20:00People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al. People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al.
The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination
globenewswire.com
2025-08-18 14:47:00Physicians file amicus brief opposing removal of religious exemptions to vaccines. Objections include components derived from pork or aborted fetal tissue.
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
zacks.com
2025-08-05 13:21:16Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
zacks.com
2025-08-05 10:56:17The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Amicus (FOLD) Q2 Revenue Jumps 22%
fool.com
2025-08-01 18:01:40Amicus (FOLD) Q2 Revenue Jumps 22%
No data to display
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy
zacks.com
2025-10-07 13:01:13Amicus Therapeutics (FOLD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns
zacks.com
2025-10-06 10:26:18Broker upgrades fuel optimism for Amicus Therapeutics, Micron and General Dynamics as earnings outlook strengthens.
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
zacks.com
2025-10-02 10:41:58Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.
3 Of My Favorite Biotech Stocks Under $10
seekingalpha.com
2025-09-29 13:15:09Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
zacks.com
2025-09-25 12:31:13Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?
zacks.com
2025-09-19 10:36:09Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
seekingalpha.com
2025-09-09 18:06:20Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 3:20 PM EDT Company Participants Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Okay. Great. I'm Max Skor, a biotech analyst with Morgan Stanley.
In NCLA Amicus Win, en Banc Federal Circuit Rules Trump's Emergency Tariffs Are Unlawful
globenewswire.com
2025-08-29 21:06:00V.O.S. Selections, Inc.; Plastic Services and Products, LCC, d/b/a Genova Pipe; MicroKits, LCC; FishUSA Inc.; Terry Precision Cycling LLC v. President Donald J. Trump, et al. V.O.S. Selections, Inc.; Plastic Services and Products, LCC, d/b/a Genova Pipe; MicroKits, LCC; FishUSA Inc.; Terry Precision Cycling LLC v. President Donald J. Trump, et al.
Multiple Jewish Organizations File Second Circuit Amicus Brief in Support of Previously Detained Tufts Student
businesswire.com
2025-08-25 16:22:00SEATTLE--(BUSINESS WIRE)--A coalition of American Jewish organizations have filed an amicus brief in the United States Court of Appeals for the Second Circuit in support of a Vermont federal court's consideration of Rümeysa Öztürk's habeas petition objecting to her then-detention. Öztürk, a Turkish national and PhD student at Tufts University, was detained this spring and held in an ICE facility in Louisiana for six weeks before a federal judge ordered her release. Öztürk was arrested under a r.
In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump
globenewswire.com
2025-08-21 18:20:00People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al. People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al.
The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination
globenewswire.com
2025-08-18 14:47:00Physicians file amicus brief opposing removal of religious exemptions to vaccines. Objections include components derived from pork or aborted fetal tissue.
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?
zacks.com
2025-08-05 13:21:16Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
zacks.com
2025-08-05 10:56:17The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Amicus (FOLD) Q2 Revenue Jumps 22%
fool.com
2025-08-01 18:01:40Amicus (FOLD) Q2 Revenue Jumps 22%